GH Research PLC — Form 6-K Summary
Reporting context: Form 6-K filed October 9, 2026, for the month of October 2026. GH Research PLC is an Ireland-based foreign private issuer.
Business update
The company announced that data from its GH001-TRD-201 and GH001-BD-202 clinical trials will be presented at the 39th European College of Neuropsychopharmacology (ECNP) annual meeting in Munich, October 10–13, 2026. Three posters are scheduled for Poster Session 2 on October 11. The filing does not disclose the trial data or clinical results.
GH Research will also sponsor an ECNP industry satellite symposium on October 10 titled “Achieving remission in treatment-resistant depression: current evidence and research on rapid-acting antidepressants.”
Financial information
This filing reports no revenue, earnings, cash flow, margin, debt, liquidity, or other financial metrics. It provides no comparable-period financial results.
Outlook, risks, and unusual items
The filing provides no financial guidance or outlook and identifies no contingencies or specific risks. It announces upcoming scientific presentations but does not characterize their findings.
Key facts to verify
- Review the ECNP posters for the actual results and details from trials GH001-TRD-201 and GH001-BD-202.
- Check subsequent company disclosures for any interpretation of the findings or updates to the clinical development program.